- Home
- OWL vs ICLR Comparison
OWL vs ICLR Comparison
Compare OWL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OWL
- ICLR
- Stock Information
- Founded
- OWL 2020
- ICLR 1990
- Country
- OWL United States
- ICLR Ireland
- Employees
- OWL N/A
- ICLR N/A
- Industry
- OWL Investment Managers
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- OWL Finance
- ICLR Health Care
- Exchange
- OWL Nasdaq
- ICLR Nasdaq
- Market Cap
- OWL 10.6B
- ICLR 14.3B
- IPO Year
- OWL N/A
- ICLR 1998
- Fundamental
- Price
- OWL $15.35
- ICLR $157.88
- Analyst Decision
- OWL Buy
- ICLR Buy
- Analyst Count
- OWL 15
- ICLR 15
- Target Price
- OWL $22.50
- ICLR $211.36
- AVG Volume (30 Days)
- OWL 14.7M
- ICLR 989.2K
- Earning Date
- OWL 10-30-2025
- ICLR 10-22-2025
- Dividend Yield
- OWL 5.83%
- ICLR N/A
- EPS Growth
- OWL 47.85
- ICLR N/A
- EPS
- OWL 0.08
- ICLR 7.47
- Revenue
- OWL $2,745,943,000.00
- ICLR $8,102,602,000.00
- Revenue This Year
- OWL $17.06
- ICLR N/A
- Revenue Next Year
- OWL $21.21
- ICLR $0.89
- P/E Ratio
- OWL $199.00
- ICLR $21.41
- Revenue Growth
- OWL 27.24
- ICLR N/A
- 52 Week Low
- OWL $14.54
- ICLR $125.10
- 52 Week High
- OWL $26.73
- ICLR $228.29
- Technical
- Relative Strength Index (RSI)
- OWL 40.65
- ICLR 33.43
- Support Level
- OWL $15.37
- ICLR $159.19
- Resistance Level
- OWL $16.34
- ICLR $167.87
- Average True Range (ATR)
- OWL 0.69
- ICLR 8.45
- MACD
- OWL -0.08
- ICLR -2.75
- Stochastic Oscillator
- OWL 31.47
- ICLR 4.93
About OWL Blue Owl Capital Inc.
Blue Owl Capital Inc is an alternative asset management firm. The company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The company conducts its operations through Blue Owl Capital Holdings LP (Blue Owl Holdings) and Blue Owl Capital Carry LP (Blue Owl Carry). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The company generates substantially all of its revenues in the United States.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.